Core Viewpoint - The article highlights the advancements in marine biomedicine in Qingdao, particularly focusing on the clinical trials of the marine polysaccharide drug BG136, which is the first of its kind in the world to enter clinical trials for cancer treatment [5][15]. Marine Biomedical Research - The Qingdao Marine Biomedical Research Institute aims to bridge the gap between scientific research and industrial application in marine biomedicine, promoting the transformation of research outcomes into marketable products [5][6]. - BG136, derived from Antarctic seaweed, activates the innate immune system to exert anti-tumor effects [6][15]. - The institute is also advancing other projects under the "Blue Pharmacy" initiative, including new drugs for chronic obstructive pulmonary disease (COPD) and hepatitis B, as well as an HPV treatment that has already been launched [6][15]. Industry Development - The Qingdao Marine Biomedical Research Institute is part of a broader strategy to create an integrated ecosystem for marine biomedical innovation, combining government, industry, academia, and finance [7]. - The marine biomedical industry in Qingdao is expected to exceed 38 billion yuan in output by 2024, with projections to reach a scale of 100 billion yuan by 2026 [15]. - The city has established a "4+2+4" marine industry system to foster emerging sectors, including marine pharmaceuticals and bio-products, while enhancing traditional industries [13][15]. Competitive Advantage - China's marine drug research capabilities rank among the top globally, with domestically developed marine drugs accounting for 28% of the global market [15]. - Qingdao has nurtured leading companies in the marine pharmaceutical sector, contributing to the formation of significant industry clusters in marine drugs, medical dressings, and health products [15].

Group 1 - The 2025 East Asia Marine Expo Marine Biomedicine Exhibition will be held in Qingdao, covering an exhibition area of 10,000 square meters with 85 participating enterprises and institutions [3][4] - The exhibition aims to build a full industry chain cooperation platform, showcasing the complete ecosystem and innovative achievements from marine biological resources to terminal biomedicine products [3][4] - Key technologies such as algal extraction are highlighted, showcasing the medicinal potential of algae, which is rich in polysaccharides, polyphenols, and other active substances [4][5] Group 2 - Leading companies in the industry, such as Qingdao Mingyue Algae Group, will present various algal functional materials and marine functional materials at the exhibition [4][5] - The exhibition will feature midstream enterprises with strong industrialization capabilities, focusing on new drug research and biopharmaceutical production [4][6] - Companies like Qingdao Guoxin Pharmaceutical, the first marine drug production enterprise in China, will showcase their innovative products, including BG136, which targets tumor immunotherapy [6][7] Group 3 - The exhibition will also gather downstream enterprises focusing on clinical application transformation and health product industrialization, including medical institutions and third-party testing organizations [6][7] - Notable products include health supplements developed by companies like Langyatai Dijia Pharmaceutical, which utilize unique marine biological components to regulate blood lipids and blood sugar [6][7] - The event aims to stimulate collaboration and innovation within the marine biomedicine sector, promoting a blue economy and a healthier future [7][8]